CytoDyn (CYDY) Non-Current Deferred Tax Liability (2012 - 2013)
CytoDyn's (CYDY) quarterly Non-Current Deferred Tax Liability came in at $155500.0 in Q2 2013, up 61.14% YoY from $96500.0 in Q2 2012, and up 61.14% on a QoQ basis from $96500.0 in Q2 2012.
CytoDyn (CYDY) Non-Current Deferred Tax Liability (2012 - 2013) Analysis & Trends
CytoDyn (CYDY) has 2 years of Non-Current Deferred Tax Liability data on file, last reported at $155500.0 in Q2 2013.
- Quarterly Non-Current Deferred Tax Liability rose 61.14% year-over-year to $155500.0 in Q2 2013, while the trailing twelve-month figure through May 2013 was $155500.0 (up 61.14% YoY) and the FY2013 annual result came in at $155500.0, up 61.14% from the prior year.
- Non-Current Deferred Tax Liability improved to $155500.0 in Q2 2013, from $96500.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $155500.0 in Q2 2013 to a low of $96500.0 in Q2 2012.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | CytoDyn | 258.01 Mn | 258.01 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2013 | 155,500.00 |
| May 31, 2013 | 155,500.00 |
| May 31, 2012 | 96,500.00 |
| May 31, 2012 | 96,500.00 |